Business Overview: DSwiss Inc (NASDAQ: DQWS)

---

Executive Summary

DSwiss, Inc. is a Nevada-incorporated holding company (originally formed May 28, 2015) that, through a chain of subsidiaries — DSwiss Holding Limited (Seychelles) ➡️ DSwiss (HK) Limited (Hong Kong) ➡️ DSwiss Sdn Bhd (Malaysia, the main operating entity) — runs a biotech nutraceutical and beauty products business. The company describes itself as a "premier biotech nutraceutical firm and turnkey Private Label ODM/OEM provider," with the tagline "Creating Beauty, Health, and the Ecosystem." Its day-to-day operations and registered office are based in Kuala Lumpur, Malaysia, while its intermediate holding structure and trademark registrations run through Hong Kong — giving it a genuinely pan-Asian, Hong Kong-linked corporate footprint even though manufacturing and headcount sit in Malaysia.

The company's core business is designing, formulating, and manufacturing (via contract/OEM arrangements) skincare, health supplements, functional foods, personal care, and pet wellness products, which it either sells under private label to third-party brand clients or markets directly through its own e-commerce channel. It reported revenue of $3.11 million in FY2024 (up from $1.47 million in FY2023) and $2.92 million in FY2025, with headcount growing from 13 to 30 full-time employees over the same period.

DSwiss matters as a micro-cap illustration of the Asia-Pacific nutraceutical/beauty ODM supply chain — a fragmented, low-barrier manufacturing and formulation niche serving brand owners across Malaysia, Singapore, Hong Kong, China, and beyond, rather than a consumer-facing branded powerhouse in its own right.

---

1. Core Business Model & How They Work

DSwiss operates an end-to-end turnkey ODM/OEM model: it takes a brand client's concept (or its own) from formulation and R&D, through regulatory licensing and certification (GMP, HACCP, JAKIM Halal, ISO, MESTI), to manufacturing, packaging, and shipping/import-export, and layers on business consultancy, market-trend analysis, and marketing/packaging design support. Most revenue comes from B2B OEM/ODM sales to third-party brand owners, supplemented by direct sales through its own e-commerce site (dswissbeauty.com) and social-media-driven marketing (Facebook, Instagram, WeChat).

 Brand Client / DSwiss Concept
            |
            v
   Formulation & R&D  --->  Regulatory Licensing
   (skincare, supplements)   (GMP / HACCP / Halal / ISO)
            |
            v
   Manufacturing & Packaging (contract/OEM facilities)
            |
            v
   Import / Export & Logistics
            |
      -------------------
      |                 |
      v                 v
 B2B OEM/ODM Sales   Direct-to-Consumer
 (private-label        E-commerce
  brand clients)      (dswissbeauty.com,
                        social media)

---

2. Business Segments

DSwiss does not report discrete financial segments; it operates as a single integrated nutraceutical/beauty manufacturing business, with revenue described only in aggregate (no disclosed category-level revenue split). Its product lines fall into broad categories:

DSwiss Product Categories
├── Functional Foods         (powders, liquids, chewable tablets, jellies, tea bags, capsules, gummies)
├── Skincare                 (serums, toners, cleansers, creams, masks, gels, lotions)
├── Health Supplements       (capsules, powders, tinctures)
├── Natural / Traditional    (herbal teas, traditional medicine formats)
├── Personal & Pet Care      (pet shampoos, pet wellness supplements)
└── Meal Replacement /       (complete-nutrition products)
    Complete Nutrition

No revenue-share breakdown by category is disclosed in the filings reviewed.

---

3. Product Portfolio

The company holds trademark registrations in Cambodia, Malaysia, Singapore, China, Hong Kong, India, Myanmar, Vietnam, and the EU (EUIPO), underscoring its multi-market branding ambitions even though it has not disclosed distinct consumer-facing brand names beyond "DSwiss."

---

4. Competitive Landscape

DSwiss's own 10-K does not name specific competitors, describing the beauty and healthcare industries only as "dynamic and rapidly evolving." In practice, a small Asia-Pacific nutraceutical/beauty ODM-OEM and direct-sales player like DSwiss competes against a mix of:

• Large branded beauty multinationals operating across its target markets (Malaysia, Hong Kong, Singapore, China) — e.g., Shiseido and L'Occitane, which compete for the same retail shelf and consumer wallet in premium skincare.
• Direct-sales / MLM wellness companies with deep Asia-Pacific distribution — e.g., Amway, Herbalife, and Nu Skin, which dominate the supplement and personal-care direct-sales channel DSwiss is trying to penetrate via distributor networks.
• Regional heritage wellness brands such as Eu Yan Sang, a Hong Kong/Singapore-rooted traditional Chinese medicine and wellness company, which competes in the natural/traditional-health category DSwiss also targets.
• Other contract ODM/OEM manufacturers across Malaysia and China offering similar turnkey private-label formulation and manufacturing services, where differentiation is largely on price, certification breadth, and speed-to-market rather than brand.

DSwiss is a sub-scale participant relative to all of the above, competing primarily on being a flexible, certified private-label manufacturer rather than as a branded consumer powerhouse.

---

5. Strategic Strengths & Risks

Strengths (moat sources):

• Regulatory/certification breadth — GMP, HACCP, JAKIM Halal, ISO, and MESTI certifications lower the barrier for brand clients needing compliant Southeast Asian manufacturing, particularly for Halal-sensitive Muslim-majority markets.
• Multi-jurisdiction trademark portfolio spanning nine countries/regions, giving some IP protection for future branded expansion.
• Vertically integrated service offering (formulation ➡️ manufacturing ➡️ regulatory ➡️ marketing support) that is attractive to smaller brand owners wanting a single turnkey partner.

Risks:

• Small scale and thin revenue base — $2.9–3.1 million in annual revenue with only 13–30 employees, limiting negotiating leverage with suppliers and clients.
• Geographic and channel concentration — the MD&A states the company currently operates its consumer channel exclusively through its own website, and its disclosed markets (Malaysia, Singapore, Indonesia, Hong Kong, China) are concentrated in a few Asia-Pacific economies subject to shared regulatory and macro risk.
• Customer concentration risk inherent to an OEM/ODM model — reliance on a limited set of brand clients for private-label orders, with no disclosed diversification metrics.
• Intense, fragmented competition from both global branded players and numerous regional contract manufacturers, with no named moat beyond certifications.
• Execution risk on stated growth plans — targeted 50% headcount growth, re-entry into China/Singapore/US, and planned M&A in healthcare/biotech/beauty are aspirational and unproven as of the filings reviewed.

---

6. Financial Overview

Revenue more than doubled from FY2023 to FY2024, largely attributed in the filings to growth in OEM/ODM sales of nutraceutical, skincare, and medical consumable supplies, before declining modestly (-6.2%) in FY2025 even as headcount more than doubled — suggesting the company was investing ahead of revenue (or absorbing cost growth without a matching top-line gain). No segment-level revenue breakdown, gross margin, or customer concentration disclosure was found in the sections reviewed.

---

7. Summary Conclusion

DSwiss, Inc. is a micro-cap, Hong Kong/Malaysia-linked beauty and nutraceutical manufacturer operating primarily as a turnkey private-label ODM/OEM provider across Southeast Asia, rather than as a branded consumer products company. Its multi-certification manufacturing base and multi-jurisdiction trademark portfolio give it a credible, if narrow, foothold serving brand clients who need compliant, flexible Southeast Asian production.

However, the company remains sub-scale, revenue-concentrated, and unproven in named-brand competition, with declining FY2025 revenue despite rising headcount, no disclosed segment economics, and stated expansion plans (new geographies, M&A, device-based wellness services) that have yet to be demonstrated. Its investment case rests on execution of these growth initiatives rather than on an established moat.